Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children, Active Treatment Arm Open-Label Extension Study (RAMSES OLE)
Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children, Active Treatment Arm Open-Label Extension Study (RAMSES OLE)
This study is enrolling participants by invitation only. This is an open-label, safety extension study for subjects who participated in the ARC007 study.
This is a Phase 3, multi-center, North American, open-label, long-term, safety extension study for eligible subjects who received AR101 therapy in the ARC007 trial (NCT03126227) and completed the study.
Key Inclusion Criteria:
Key Exclusion Criteria:
Mountain View, California 94040, United States
San Diego, California 92123, United States
San Francisco, California 95148, United States
San Jose, California 95117, United States
Tampa, Florida 33613, United States
Ann Arbor, Michigan 48106, United States
Rochester, New York 14642, United States
Chapel Hill, North Carolina 27599, United States
Oklahoma City, Oklahoma 73131, United States